Pharmacologic management of the older patient with type 2 diabetes mellitus

American Journal Geriatric Pharmacotherapy

Volumn 7, Issue 6, 2009, Pages 324-342

  Neumiller, Joshua J ^a   Setter, Stephen M ^a  

^a WASHINGTON STATE UNIVERSITY   (United States)

Author keywords

elderly; geriatric; pharmacologic management; type 2 diabetes mellitus

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ACARBOSE; ALPHA GLUCOSIDASE INHIBITOR; ANTIDIABETIC AGENT; BIGUANIDE DERIVATIVE; BILE ACID SEQUESTRANT; CHLORPROPAMIDE; COLESEVELAM; DIPEPTIDYL PEPTIDASE IV INHIBITOR; EXENDIN 4; GLIBENCLAMIDE; GLIMEPIRIDE; GLIPIZIDE; INSULIN; INSULIN DETEMIR; INSULIN GLARGINE; ISOPHANE INSULIN; MEGLITINIDE; METFORMIN; NATEGLINIDE; PIOGLITAZONE; PLACEBO; PRAMLINTIDE; REPAGLINIDE; ROSIGLITAZONE; SAXAGLIPTIN; SITAGLIPTIN; SULFONYLUREA; SULFONYLUREA DERIVATIVE; UNINDEXED DRUG;

ADD ON THERAPY; ANEMIA; ARTICLE; BEDTIME DOSAGE; CLINICAL TRIAL; CONSTIPATION; CREATININE CLEARANCE; DIARRHEA; DOSAGE SCHEDULE COMPARISON; DOSE RESPONSE; DRUG ADSORPTION; DRUG CLEARANCE; DRUG DOSE TITRATION; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; DYSGEUSIA; DYSPEPSIA; ELDERLY CARE; EVENING DOSAGE; FLATULENCE; FLUID RETENTION; FRACTURE; GASTROINTESTINAL SYMPTOM; GERIATRIC PATIENT; GLYCEMIC CONTROL; HEADACHE; HEALTH CARE PLANNING; HUMAN; HYPOGLYCEMIA; LACTIC ACIDOSIS; LIVER FUNCTION TEST; METABOLIC DISORDER; MYALGIA; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; PERIPHERAL EDEMA; PRIORITY JOURNAL; RECOMMENDED DRUG DOSE; RISK MANAGEMENT; SIDE EFFECT; STROKE; TREATMENT CONTRAINDICATION; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION; VOMITING; WEIGHT GAIN;

AGED; AGING; ALPHA-GLUCOSIDASES; AMYLOID; BILE ACIDS AND SALTS; DIABETES MELLITUS, TYPE 2; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN;

EID: 74549169228     PISSN: 15435946     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjopharm.2009.12.002     Document Type: Article

References (113)

1. DeFronzo R.A. Pathogenesis of type 2 diabetes mellitus. Med Clin North Am. 88 (2004) 787-835
2. Centers for Disease Control and Prevention. National diabetes fact sheet. United States, 2005. http://apps.nccd.cdc.gov/DDTSTRS/template/ndfs_2005.pdf Accessed September 20, 2009
3. Mathieu C., and Bollaerts K. Antihyperglycaemic therapy in elderly patients with type 2 diabetes: Potential role of incretin mimetics and DPP-4 inhibitors. Int J Clin Pract Suppl. 61 (2007) 29-37
4. American Diabetes Association. Diabetes statistics. http://www.diabetes.org/diabetes-basics/diabetesstatistics/ Accessed November 18, 2009
5. Hsu J., Fung V., Price M., et al. Medicare beneficiaries' knowledge of Part D prescription drug program benefits and responses to drug costs. JAMA. 299 (2008) 1929-1936
6. Madden J.M., Graves A.J., Zhang F., et al. Cost-related medication nonadherence and spending on basic needs following implementation of Medicare Part D. JAMA. 299 (2008) 1922-1928
7. American Diabetes Association. Standards of medical care in diabetes-2009. Diabetes Care 32 Suppl 1 (2009) S13-S61
8. UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34) [published correction appears in Lancet. 1998;352:1558]. Lancet. 352 (1998) 854-865
9. Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 329 (1993) 977-986
10. Heart Outcomes Prevention Evaluation Study Investigators. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: Results of the HOPE study and MICRO-HOPE substudy [published correction appears in Lancet. 2000;356:860]. Lancet. 355 (2000) 253-259
11. Brown A.F., Mangione C.M., Saliba D., Sarkisian C.A., and California Healthcare Foundation/American Geriatrics Society Panel on Improving Care for Elders with Diabetes. Guidelines for improving the care of the older person with diabetes mellitus. J Am Geriatr Soc. 51 Suppl 5 (2003) S265-S280
12. Pyörälä K., Pedersen T.R., Kjekshus J., et al. Cholesterol lowering with simvastatin improves prognosis of diabeticpatients with coronary heart disease. A subgroup analysis of the Scandinavian Simvastatin Survival Study (4S) [published correction appears in Diabetes Care. 1997; 20:1048]. Diabetes Care. 20 (1997) 614-620
13. Curb J.D., Pressel S.L., Cutler J.A., et al., Systolic Hypertension in the Elderly Program Cooperative Research Group. Effect of diuretic-based antihypertensive treatment on cardiovascular disease risk in older diabetic patients with isolated systolic hypertension [published correction appears in JAMA. 1997;277:1356]. JAMA. 276 (1996) 1886-1892
14. Holman R.R., Paul S.K., Bethel M.A., et al. 10-Year followup of intensive glucose control in type 2 diabetes. N Engl J Med. 359 (2008) 1577-1589
15. Patel A., MacMahon S., Chalmers J., et al., ADVANCE Collaborative Group. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med. 358 (2008) 2560-2572
16. Gerstein H.C., Miller M.E., Byington R.P., et al., Action to Control Cardiovascular Risk in Diabetes Study Group. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med. 358 (2008) 2545-2559
17. Lindeman R.D., Tobin J., and Shock N.W. Longitudinal studies on the rate of decline in renal function with age. J Am Geriatr Soc. 33 (1985) 278-285
18. O'Malley K., Crooks J., Duke E., and Stevenson I.H. Effect of age and sex on human drug metabolism. Br Med J. 3 (1971) 607-609
19. Mangoni A.A., and Jackson S.H. Age-related changes in pharmacokinetics and pharmacodynamics: Basic principles and practical applications. Br J Clin Pharmacol. 57 (2004) 6-14
20. Turnheim K. Drug therapy in the elderly. Exp Gerontol. 39 (2004) 1731-1738
21. Greenblatt D.J., Harmatz J.S., and Shader R.I. Clinical pharmacokinetics of anxiolytics and hypnotics in the elderly. Therapeutic considerations (Part I). Clin Pharmacokinet. 21 (1991) 165-177
22. Fülöp Jr. T., Wórum I., Csongor J., et al. Determination of body composition by multiisotope method and the elimination kinetics of these isotopes in healthy elderly subjects. Gerontology. 31 (1985) 6-14
23. Turnheim K. Drug dosage in the elderly. Is it rational?. Drugs Aging. 13 (1998) 357-379
24. Fick D.M., Cooper J.W., Wade W.E., et al. Updating the Beers criteria for potentially inappropriate medication use in older adults: Results of a US consensus panel of experts [published correction appears in Arch Intern Med. 2004;164:298]. Arch Intern Med. 163 (2003) 2716-2724
25. Graal M.B., and Wolffenbuttel B.H. The use of sulphonylureas in the elderly. Drugs Aging. 15 (1999) 471-481
26. ElDesoky E.S. Pharmacokinetic-pharmacodynamic crisis in the elderly. Am J Ther. 14 (2007) 488-498
27. Haas L. Management of diabetes mellitus medications in the nursing home. Drugs Aging. 22 (2005) 209-218
28. Cayea D., Boyd C., and Durso S.C. Individualising therapy for older adults with diabetes mellitus. Drugs Aging. 24 (2007) 851-863
29. Setter S.M., Iltz J.L., Thams J., and Campbell R.K. Metformin hydrochloride in the treatment of type 2 diabetes mellitus: A clinical review with a focus on dual therapy. Clin Ther. 25 (2003) 2991-3026
30. Kirpichnikov D., McFarlane S.I., and Sowers J.R. Metformin: An update. Ann Intern Med. 137 (2002) 25-33
31. Glucophage/Glucophage XR [package insert] (2009), Bristol-Myers Squibb Company, Princeton, NJ
32. Brown J.B., Pedula K., Barzilay J., et al. Lactic acidosis rates in type 2 diabetes [published correction appears in Diabetes Care. 1998;21:2203]. Diabetes Care. 21 (1998) 1659-1663
33. Bolen S., Feldman L., Vassy J., et al. Systematic review: Comparative effectiveness and safety of oral medications for type 2 diabetes mellitus [published correction appears in Ann Intern Med. 2007;147:887]. Ann Intern Med. 147 (2007) 386-399
34. van Staa T., Abenhaim L., and Monette J. Rates of hypoglycemia in users of sulfonylureas. J Clin Epidemiol. 50 (1997) 735-741
35. Hornick T., and Aron D.C. Managing diabetes in the elderly: Go easy, individualize. Cleve Clin J Med. 75 (2008) 70-78
36. Chelliah A., and Burge M.R. Hypoglycemia in elderly patients with diabetes mellitus: Causes and strategies for prevention. Drugs Aging. 21 (2004) 511-530
37. Holstein A., Plaschke A., and Egberts E.H. Lower incidence of severe hypoglycaemia in patients with type 2 diabetes treated with glimepiride versus glibenclamide. Diabetes Metab Res Rev. 17 (2001) 467-473
38. Yki-Järvinen H. Thiazolidinediones. N Engl J Med. 351 (2004) 1106-1118
39. Nesto R.W., Bell D., Bonow R.O., et al. Thiazolidinedione use, fluid retention, and congestive heart failure: A consensus statement from the American Heart Association and American Diabetes Association. Diabetes Care. 27 (2004) 256-263
40. Inzucchi S.E. Oral antihyperglycemic therapy for type 2 diabetes: Scientific review. JAMA. 287 (2002) 360-372
41. US Food and Drug Administration. Safety alert. Avandia (rosiglitazone maleate/metformin HCl). http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm150496.htm Accessed July 3, 2009
42. Kahn S.E., Zinman B., Lachin J.M., et al., Diabetes Outcome Progression Trial (ADOPT) Study Group. Rosiglitazone-associated fractures in type 2 diabetes: An Analysis from A Diabetes Outcome Progression Trial (ADOPT). Diabetes Care. 31 (2008) 845-851
43. Meier C., Kraenzlin M.E., Bodmer M., et al. Use of thiazolidinediones and fracture risk. Arch Intern Med. 168 (2008) 820-825
44. Schwartz A.V., and Sellmeyer D.E. Effect of thiazolidinediones on skeletal health in women with Type 2 diabetes. Expert Opin Drug Saf. 7 (2008) 69-78
45. Singh S., Loke Y.K., and Furberg C.D. Long-term risk of cardiovascular events with rosiglitazone: A meta-analysis. JAMA. 298 (2007) 1189-1195
46. Nissen S.E., and Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes [published correction appears in N Engl J Med. 2007;357:100]. N Engl J Med. 356 (2007) 2457-2471
47. Lincoff A.M., Wolski K., Nicholls S.J., and Nissen S.E. Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: A meta-analysis of randomized trials. JAMA. 298 (2007) 1180-1188
48. Home P.D., Pocock S.J., Beck-Nielsen H., et al., RECORD Study Team. Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): A multicentre, randomized, open-label trial. Lancet. 373 (2009) 2125-2135
49. Lipscombe L.L., Gomes T., Lévesque L.E., et al. Thiazolidinediones and cardiovascular outcomes in older patients with diabetes. JAMA. 298 (2007) 2634-2643
50. Winkelmayer W.C., Setoguchi S., Levin R., and Solomon D.H. Comparison of cardiovascular outcomes in elderly patients with diabetes who initiated rosiglitazone vs pioglitazone therapy. Arch Intern Med. 168 (2008) 2368-2375
51. Campbell R.K. Rationale for dipeptidyl peptidase 4 inhibitors: A new class of oral agents for the treatment of type 2 diabetes mellitus. Ann Pharmacother. 41 (2007) 51-60
52. Barnett A. DPP-4 inhibitors and their potential role in the management of type 2 diabetes. Int J Clin Pract. 60 (2006) 1454-1470
53. National Institute for Health and Clinical Excellence. CG87 Type 2 diabetes-newer agents (a partial update of CG66): Short guideline. http://www.nice.org.uk/CG87shortguideline Accessed July 3, 2009
54. Januvia [package insert] (2009), Merck & Co, Inc, Whitehouse Station, NJ
55. WelChol [package insert] (2009), Daiichi Sankyo, Inc, Parsippany, NJ
56. Staels B. A review of bile acid sequestrants: Potential mechanism(s) for glucose-lowering effects in type 2 diabetes mellitus. Postgrad Med. 121 Suppl 1 (2009) 25-30
57. Staels B., and Kuipers F. Bile acid sequestrants and the treatment of type 2 diabetes mellitus. Drugs. 67 (2007) 1383-1392
58. Zieve F.J., Kalin M.F., Schwartz S.L., et al. Results of the Glucose-Lowering Effect of WelChol Study (GLOWS): A randomized, double-blind, placebo-controlled pilot study evaluating the effect of colesevelam hydrochloride on glycemic control in subjects with type 2 diabetes. Clin Ther. 29 (2007) 74-83
59. Bays H., and Jones P.H. Colesevelam hydrochloride: Reducing atherosclerotic coronary heart disease risk factors. Vasc Health Risk Manag. 3 (2007) 733-742
60. Barnett A. Exenatide. Expert Opin Pharmacother. 8 (2007) 2539-2608
61. Odegard P.S., Setter S.M., and Iltz J.L. Update in the pharmacologic treatment of diabetes mellitus: Focus on pramlintide and exenatide. Diabetes Educ. 32 (2006) 693-712
62. Buse J.B., Henry R.R., Han J., et al., Exenatide-113 Clinical Study Group. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes. Diabetes Care. 27 (2004) 2628-2635
63. DeFronzo R.A., Ratner R.E., Han J., et al. Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes. Diabetes Care. 28 (2005) 1092-1100
64. Kendall D.M., Riddle M.C., Rosenstock J., et al. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea. Diabetes Care. 28 (2005) 1083-1091
65. Linnebjerg H., Kothare P.A., Park S., et al. Effect of renal impairment on the pharmacokinetics of exenatide. Br J Clin Pharmacol. 64 (2007) 317-327
66. Odegard P.S., Setter S.M., and Neumiller J.J. Considerations for the pharmacological treatment of diabetes in older adults. Diabetes Spectrum. 20 (2007) 239-247
67. Byetta injection [package insert] (2009), Amylin Pharmaceuticals, Inc, San Diego, Calif
68. Zinman B., Hoogwerf B.J., Dúran G.S., et al. The effect of adding exenatide to thiazolidinedione in suboptimally controlled type 2 diabetes: A randomized trial [published correction appears in Ann Intern Med. 2007;146:896]. Ann Intern Med. 146 (2007) 477-485
69. US Food and Drug Administration. Safety alert. Byetta (exenatide)-renal failure. http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm188703.htm Accessed April 30, 2009
70. Symlin injection [package insert] (2008), Amylin Pharmaceuticals, Inc, San Diego, Calif
71. Borm A.K., Klevesath M.S., Borcea V., et al. The effect of pramlintide (amylin analogue) treatment on bone metabolism and bone density in patients with type 1 diabetes mellitus. Horm Metab Res. 31 (1999) 472-475
72. Diabetes mellitus. Omnicare Geriatric Pharmaceutical Care Guidelines (2009), Omnicare, Inc, Covington, UK 349-372 2009 ed
73. Amaryl tablets [package insert] (2005), sanofiaventis US, Bridgewater, NJ
74. Glucotrol [package insert] (2000), Pfizer Inc, New York, NY
75. Diabeta [package insert] (2009), sanofi-aventis US, Bridgewater, NJ
76. Prandin [package insert] (2006), Novo Nordisk Pharmaceuticals, Inc, Princeton, NJ
77. Starlix [package insert] (2008), Novartis Pharmaceuticals Corporation, East Hanover, NJ
78. Actos [package insert] (2009), Takeda Pharmaceuticals Inc, Deerfield, Ill
79. Avandia [package insert] (2008), GlaxoSmithKline, Research Triangle Park, NC
80. Onglyza [package insert] (2009), Bristol-Myers Squibb Company, Princeton, NJ
81. Precose [package insert] (2008), Bayer Pharmaceuticals Corporation, West Haven, Conn
82. Glyset tablets [package insert] (2008), Pfizer Inc, New York, NY
83. Budnitz D.S., Shehab N., Kegler S.R., and Richards C.L. Medication use leading to emergency department visits for adverse drug events in older adults. Ann Intern Med. 147 (2007) 755-765
84. Rosenstock J. Management of type 2 diabetes mellitus in the elderly: Special considerations. Drugs Aging. 18 (2001) 31-44
85. Vischer U.M., Bauduceau B., Bourdel-Marchasson I., et al., Alfediam/SFGG French-Speaking Group for Study of Diabetes in the Elderly. A call to incorporate the prevention and treatment of geriatric disorders in the management of diabetes in the elderly. Diabetes Metab. 35 (2009) 168-177
86. Humalog [package insert] (2009), Eli Lilly and Company, Indianapolis, Ind
87. NovoLog [package insert] (2009), Novo Nordisk Pharmaceuticals, Inc, Princeton, NJ
88. Apidra [package insert] (2009), sanofi-aventis US, Bridgewater, NJ
89. Humulin R [package insert] (2007), Eli Lilly and Company, Indianapolis, Ind
90. Novolin R Innolet [package insert] (2003), Novo Nordisk Pharmaceuticals, Inc, Princeton, NJ
91. Humulin N [package insert] (2009), Eli Lilly and Company, Indianapolis, Ind
92. Novolin N Innolet [package insert] (2004), Novo Nordisk Pharmaceuticals, Inc, Princeton, NJ
93. Lantus [package insert] (2007), sanofi-aventis US, Bridgewater, NJ
94. Levemir [package insert] (2009), Novo Nordisk Pharmaceuticals, Inc, Princeton, NJ
95. Humulin 70/30 [package insert] (2007), Eli Lilly and Company, Indianapolis, Ind
96. Novolin 70/30 Innolet [package insert] (2004), Novo Nordisk Pharmaceuticals, Inc, Princeton, NJ
97. Humulin 50/50 [package insert] (2007), Eli Lilly and Company, Indianapolis, Ind
98. NovoLog Mix 70/30 [package insert] (2009), Novo Nordisk Pharmaceuticals, Inc, Princeton, NJ
99. Humalog Mix75/25 [package insert] (2009), Eli Lilly and Company, Indianapolis, Ind
100. Humalog Mix50/50 [package insert] (2009), Eli Lilly and Company, Indianapolis, Ind
101. Coscelli C., Lostia S., Lunetta M., et al. Safety, efficacy, acceptability of a pre-filled insulin pen in diabetic patients over 60 years old. Diabetes Res Clin Pract. 28 (1995) 173-177
102. Nathan D.M., Buse J.B., Davidson M.B., et al., American Diabetes Association and the European Association for the Study of Diabetes. Medical management of hyperglycemia in type 2 diabetes: A consensus algorithm for the initiation and adjustment of therapy: A consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 32 (2009) 193-203
103. Janka H.U., Plewe G., and Busch K. Combination of oral antidiabetic agents with basal insulin versus premixed insulin alone in randomized elderly patients with type 2 diabetes mellitus. J Am Geriatr Soc. 55 (2007) 182-188
104. Rosenstock J., Schwartz S.L., Clark Jr. C.M., et al. Basal insulin therapy in type 2 diabetes: 28-Week comparison of insulin glargine (HOE 901) and NPH insulin. Diabetes Care. 24 (2001) 631-636
105. Hermansen K., Davies M., Derezinski T., et al. A 26-week, randomized, parallel, treat-to-target trial comparing insulin detemir with NPH insulin as add-on therapy to oral glucose-lowering drugs in insulin-naive people with type 2 diabetes [published correction appears in Diabetes Care. 2007;30:1035]. Diabetes Care. 29 (2006) 1269-1274
106. Philis-Tsimikas A., Charpentier G., Clauson P., et al. Comparison of once-daily insulin detemir with NPH insulin added to a regimen of oral antidiabetic drugs in poorly controlled type 2 diabetes [published correction appears in Clin Ther. 2006;28:1967]. Clin Ther. 28 (2006) 1569-1581
107. Mooradian A.D., Bernbaum M., and Albert S.G. Narrative review: A rational approach to starting insulin therapy. Ann Intern Med. 145 (2006) 125-134
108. Zarowitz B.J., Tangalos E.G., Hollenack K., and O'Shea T. The application of evidence-based principles of care in older persons (issue 3): Management of diabetes mellitus. J Am Med Dir Assoc. 7 (2006) 234-240
109. Coscelli C., Calabrese G., Fedele D., et al. Use of premixed insulin among the elderly. Reduction of errors in patient preparation of mixtures. Diabetes Care. 15 (1992) 1628-1630
110. Rolla A.R., and Rakel R.E. Practical approaches to insulin therapy for type 2 diabetes mellitus with premixed insulin analogues. Clin Ther. 27 (2005) 1113-1125
111. Raskin P., Allen E., Hollander P., et al., INITIATE Study Group. Initiating insulin therapy in type 2 diabetes: A comparison of biphasic and basal insulin analogs. Diabetes Care. 28 (2005) 260-265
112. Korytkowski M. When oral agents fail: Practical barriers to starting insulin. Int J Obes Relat Metab Disord. 26 Suppl 3 (2002) S18-S24
113. Reza M., Taylor C.D., Towse K., et al. Insulin improves well-being for selected elderly type 2 diabetic subjects. Diabetes Res Clin Pract. 55 (2002) 201-207